| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
London Health Sciences Centre, University of Western Ontario, London, Ontario N6A 5A5, Canada
a Address correspondence to this author at: Department of Medicine, London Health Sciences Centre—University Campus, 339 Windermere Rd., London, Ontario, N6A 5A5 Canada. Fax 519-663-3232; e-mail padams{at}julian.uwo.ca
 |
To the Editor: |
|---|
 Top To the Editor: References |
|---|
"Discovered" cases refers to C282Y homozygotes found through pedigree studies, and "screened" cases refers to cases discovered during a population screening project in 5211 voluntary blood donors (2). The sample consisted of 78 male probands, 58 discovered men, 5 screened men, 26 female probands, 37 discovered women, and 11 screened women. All hemochromatosis patients and control cases had C282Y genotyping by Rsa1 restriction enzyme digestion (3). Homozygotes with a normal TS and ferritin (n = 5) were confirmed by direct DNA sequencing to exclude false-positive genetic testing (4).
Serum iron was determined by colorimetric analysis (Roche Diagnostics or Beckman Coulter). UIBC was determined on the Beckman Coulter LX-20 (Reagent 153-50; Diagnostic Chemicals Limited) or by adapting an existing assay to an automated microwell plate reader (Unimate 7 UIBC; Roche Diagnostics). TS by UIBC was directly compared with TS determined by immunochemical transferrin on the Beckman Coulter IMMAGE immunochemistry system (correlation coefficient = 0.986; n = 192). Between-run precision of UIBC was determined by measuring three levels of control daily for 31 days. CVs were 2.8–7.2%.
The diagnostic accuracy of UIBC and TS for the diagnosis of C282Y
homozygotes was examined by ROC curve analysis with a program
developed at this medical center (5). UIBC data were
transformed to 1/UIBC for direct comparison to TS. The thresholds were
determined from the ROC curves on the basis of the likelihood ratios
[sensitivity/(1 - specificity)]. The areas under the curves
were 0.96 (95% confidence interval, 0.94–0.98) for 1/UIBC and 0.96
(95% confidence interval, 0.94–0.98) for TS. Thresholds were 
44%
(sensitivity, 88%; specificity, 99%) for TS and 
27 µmol/L
(sensitivity, 88%; specificity, 98%) for UIBC (Table 1
). These thresholds are similar to those determined in the screening of
5211 blood donors in which the UIBC detected more C282Y homozygotes
with fewer false positives and at a reduced cost (2).
|
These results raise the question stated in the title of this Letter. The cost of the UIBC assay in this study was estimated to be $1. It is intuitive that, using any cost-analysis system, the cost of the single-step UIBC will be less than the cost of the two-step assay using serum iron plus UIBC, total iron-binding capacity, or transferrin. In the less-common cases of hemochromatosis that are not associated with HFE mutations, the disease is defined by iron overload, and thus both UIBC and TS would be expected to be abnormal. UIBC has been used successfully in other studies that screened for hemochromatosis without genotyping in all patients (6)(7). Therefore, UIBC, which has been used for large-scale population screening studies (8), appears to perform as well as TS as a screening test for hemochromatosis at a reduced cost.
|
References |
|---|
|
TopTo the Editor:References |
|---|
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  J. Waalen, V. J. Felitti, T. Gelbart, and E. Beutler Screening for hemochromatosis by measuring ferritin levels: a more effective approach Blood, April 1, 2008; 111(7): 3373 - 3376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Adams, D. M. Reboussin, C. Leiendecker-Foster, G. C. Moses, G. D. McLaren, C. E. McLaren, F. W. Dawkins, I. Kasvosve, R. T. Acton, J. C. Barton, et al. Comparison of the Unsaturated Iron-Binding Capacity with Transferrin Saturation as a Screening Test to Detect C282Y Homozygotes for Hemochromatosis in 101 168 Participants in the Hemochromatosis and Iron Overload Screening (HEIRS) Study Clin. Chem., June 1, 2005; 51(6): 1048 - 1052. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
